Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban
Drug: Clopidogrel

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02265289

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: telmisartan
Drug: ASA/ER-DP

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262793

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole Placebo
Drug: Pramipexole extended-release (ER) tablets
Drug: Moxifloxacin
Drug: Moxifloxacin Placebo
Drug: Pramipexole immediate-release (IR) tablets

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02262546

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan /HCTZ - compression tablet (DC)
Drug: Telmisartan /HCTZ - dry granulation tablet (DG)
Drug: Telmisartan /HCTZ - present commercial formulation

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262572

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: MicardisPlus®

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4814

Registration Number: NCT02262637

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/HCTZ fixed dose
Drug: Telmisartan
Drug: Hydrochlorthiazide (HCTZ)

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02262598

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 277 capsule
Drug: BIBR 277 tablet

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02262559

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan and HCTZ
Drug: Telmisartan
Drug: HCTZ

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT02262858

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Clopidogrel

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262650

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 277 capsule
Drug: BIBR 277 tablet

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02262585

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy